Tiba Biotech

Tiba Biotech is a Cambridge, Massachusetts preclinical biotech spun out of MIT and the Whitehead Institute that is building a new generation of RNA vaccines and therapeutics. Its RNABL platform swaps the fragile lipid nanoparticles behind first-generation mRNA shots for fully synthetic, biodegradable dendrimer nanoparticles that carry larger RNA payloads with less toxicity and gentler cold-chain demands. The company is applying the technology across human vaccines, cancer immunotherapy, gene editing delivery, and animal health, backed by CEPI, BARDA, the NIH, and the NCI.